Inhibition of hepatitis C virus replication by arsenic trioxide

Antimicrobial Agents and Chemotherapy

Volumn 48, Issue 8, 2004, Pages 2876-2882

  Hwang, Der Ren ^a   Tsai, Yuan Chin ^a   Lee, Jin Ching ^a   Huang, Kuo Kuei ^a   Lin, Ren Kuo ^a   Ho, Chia Hua ^a   Chiou, Jeng Min ^a   Lin, Ying Ting ^a   Hsu, John T A ^a,c   Yeh, Chau Ting ^a,b  

^a NATIONAL HEALTH RESEARCH INSTITUTES   (Taiwan)

^b CHANG GUNG MEMORIAL HOSPITAL   (Taiwan)

^c NATIONAL TSING HUA UNIVERSITY   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; ARSENIC TRIOXIDE;

ARTICLE; CONTROLLED STUDY; CYTOTOXICITY; DRUG POTENTIATION; HEPATITIS C VIRUS; HUMAN; HUMAN CELL; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; STATISTICAL MODEL; VIRUS INHIBITION; VIRUS REPLICATION;

ANTIVIRAL AGENTS; ARSENICALS; BLOTTING, NORTHERN; BLOTTING, WESTERN; CELL LINE; DRUG EVALUATION, PRECLINICAL; DRUG SYNERGISM; GENES, REPORTER; HEPACIVIRUS; HUMANS; INTERFERON-ALPHA; OXIDES; REPLICON; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, VIRAL; VIRUS REPLICATION;

EID: 3343022576     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.48.8.2876-2882.2004     Document Type: Article

References (41)

1. Ago, H., T. Adachi, A. Yoshida, M. Yamamoto, N. Habuka, K. Yatsunami, and M. Miyano. 1999. Crystal structure of the RNA-dependent RNA polymerase of hepatitis C virus. Structure Fold Des. 7:1417-1426.
2. Bartenschlager, R. 2002. Hepatitis C virus replicons: potential role for drug development. Nat. Rev. Drug Discov. 1:911-916.
3. Berleth, E. S., and C. M. Pickart. 1996. Mechanism of ubiquitin conjugating enzyme E2-230K: catalysis involving a thiol relay? Biochemistry 35:1664-1671.
4. Bhattacharjee, H., and B. P. Rosen. 1996. Spatial proximity of Cys113, Cys172, and Cys422 in the metalloactivation domain of the ArsA ATPase. J. Biol. Chem. 271:24465-24470.
5. Blight, K. J., A. A. Kolykhalov, and C. M. Rice. 2000. Efficient initiation of HCV RNA replication in cell culture. Science 290:1972-1974.
6. Bressanelli, S., L. Tomei, F. A. Rey, and R. De Francesco. 2002. Structural analysis of the hepatitis C virus RNA polymerase in complex with ribonucleotides. J. Virol. 76:3482-3492.
7. Bressanelli, S., L. Tomei, A. Roussel, I. Incitti, R. L. Vitale, M. Mathieu, R. De Francesco, and F. A. Rey. 1999. Crystal structure of the RNA-dependent RNA polymerase of hepatitis C virus. Proc. Natl. Acad. Sci. USA 96:13034-13039.
8. 3 dose-dependent dual effects on APL cells. Blood 89:3345-3353.
9. Chen, Z., G. Q. Chen, Z. X. Shen, G. L. Sun, J. H. Tong, Z. Y. Wang, and S. J. Chen. 2002. Expanding the use of arsenic trioxide: leukemias and beyond. Semin. Hematol. 39:22-26.
10. Choo, Q. L., G. Kuo, A. J. Weiner, L. R. Overby, D. W. Bradley, and M. Houghton. 1989. Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome. Science 244:359-362.
11. Cory, A. H., T. C. Owen, J. A. Barltrop, and J. G. Cory. 1991. Use of an aqueous soluble tetrazolium/formazan assay for cell growth assays in culture. Cancer Commun. 3:207-212.
12. Cunningham, M. L., M. J. Zvelebil, and A. H. Fairlamb. 1994. Mechanism of inhibition of trypanothione reductase and glutathione reductase by trivalent organic arsenicals. Eur. J. Biochem. 221:285-295.
13. Fried, M. W., M. L. Shiffman, K. R. Reddy, C. Smith, G. Marinos, F. L. Goncales, Jr., D. Haussinger, M. Diago, G. Carosi, D. Dhumeaux, A. Craxi, A. Lin, J. Hoffman, and J. Yu. 2002. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N. Engl. J. Med. 347:975-982.
14. Greco, W. R., G. Bravo, and J. C. Parsons. 1995. The search for synergy: a critical review from a response surface perspective. Pharmacol. Rev. 47:331-385.
15. Hartwig, A., A. Pelzer, M. Asmuss, and A. Burkle. 2003. Very low concentrations of arsenite suppress poly(ADP-ribosyl)ation in mammalian cells. Int. J. Cancer 104:1-6.
16. Hewlett, P. S. 1969. Measurement of the potencies of drug mixtures. Biometrics 25:477-487.
17. Hsu, T. A., J. J. Eiden, P. Bourgarel, T. Meo, and M. J. Betenbaugh. 1994. Effects of co-expressing chaperone BiP on functional antibody production in the baculovirus system. Protein Expr. Purif. 5:595-603.
18. Kapahi, P., T. Takahashi, G. Natoli, S. R. Adams, Y. Chen, R. Y. Tsien, and M. Karin. 2000. Inhibition of NF-kappa B activation by arsenite through reaction with a critical cysteine in the activation loop of IκB kinase. J. Biol. Chem. 275:36062-36066.
19. Keskinen, P., K. Melen, and I. Julkunen. 2002. Expression of HCV structural proteins impairs IFN-mediated antiviral response. Virology 299:164.
20. Kevil, C. G., L. Walsh, F. S. Laroux, T. Kalogeris, M. B. Grisham, and J. S. Alexander. 1997. An improved, rapid Northern protocol. Biochem. Biophys. Res. Commun. 238:277-279.
21. Lauer, G. M., and B. D. Walker. 2001. Hepatitis C virus infection. N. Engl. J. Med. 345:41-52.
22. Lee, J.-C., C.-F. Chang, Y.-H. Chi, D.-R. Hwang, and J. T.-A. Hsu. 2004. A reporter-based assay for identifying hepatitis C virus inhibitors based on subgenomic replicon cells. J. Virol. Methods 116:27-33.
23. Lee, J. C., Y. F. Shih, S. P. Hsu, T. Y. Chang, L. H. Chen, and J. T. Hsu. 2003. Development of a cell-based assay for monitoring specific hepatitis C virus NS3/4A protease activity in mammalian cells. Anal. Biochem. 316:162-170.
24. Lesburg, C. A., M. B. Cable, E. Ferrari, Z. Hong, A. F. Mannarino, and P. C. Weber. 1999. Crystal structure of the RNA-dependent RNA polymerase from hepatitis C virus reveals a fully encircled active site. Nat. Struct. Biol. 6:937-943.
25. Liang, T. J., B. Rehermann, L. B. Seeff, and J. H. Hoofnagle. 2000. Pathogenesis, natural history, treatment, and prevention of hepatitis C. Ann. Intern. Med. 132:296-305.
26. Lohmann, V., F. Korner, J. Koch, U. Herian, L. Theilmann, and R. Bartenschlager. 1999. Replication of subgenomic hepatitis C virus RNAs in a hepatoma cell line. Science 285:110-113.
27. Lu, D.-P., J.-Y. Qiu, B. Jiang, Q. Wang, K.-Y. Liu, Y.-R. Liu, and S.-S. Chen. 2002. Tetra-arsenic tetra-sulfide for the treatment of acute promyelocytic leukemia: a pilot report. Blood 99:3136-3143.
28. Lu, D. P., and Q. Wang. 2002. Current study of APL treatment in China. Int. J. Hematol. 76(Suppl. 1):316-318.
29. Machado, S. G., and G. A. Robinson. 1994. A direct, general approach based on isobolograms for assessing the joint action of drugs in pre-clinical experiments. Stat. Med. 13:2289-2309.
30. McHutchison, J. G., and M. W. Fried. 2003. Current therapy for hepatitis C: pegylated interferon and ribavirin. Clin. Liver Dis. 7:149-161.
31. McHutchison, J. G., S. C. Gordon, E. R. Schiff, M. L. Shiffman, W. M. Lee, V. K. Rustgi, Z. D. Goodman, M. H. Ling, S. Cort, J. K. Albrecht, et al. 1998. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. N. Engl. J. Med. 339:1485-1492.
32. Miller, W. H., Jr., H. M. Schipper, J. S. Lee, J. Singer, and S. Waxman. 2002. Mechanisms of action of arsenic trioxide, Cancer Res. 62:3893-3903.
33. Nasr, R., A. Rosenwald, M. E. El-Sabban, B. Arnulf, P. Zalloua, Y. Lepelletier, F. Bex, O. Hermine, L. Staudt, H. de The, and A. Bazarbachi. 2003. Arsenic/interferon specifically reverses 2 distinct gene networks critical for the survival of HTLV-1-infected leukemic cells. Blood 101:4576-4582.
34. Poynard, T., P. Marcellin, S. S. Lee, C. Niederau, G. S. Minuk, G. Ideo, V. Bain, J. Heathcote, S. Zeuzem, C. Trepo, J. Albrecht, et al. 1998. Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. Lancet 352:1426-1432.
35. Stuyver, L. J., T. R. McBrayer, P. M. Tharnish, A. E. Hassan, C. K. Chu, K. W. Pankiewicz, K. A. Watanabe, R. F. Schinazi, and M. J. Otto. 2003. Dynamics of subgenomic hepatitis C virus replicon RNA levels in Huh-7 cells after exposure to nucleoside antimetabolites. J. Virol. 77:10689-10694.
36. Taylor, D. R., S. T. Shi, and M. M. Lai. 2000. Hepatitis C virus and interferon resistance. Microbes Infect. 2:1743-1756.
37. Waxman, S., and K. C. Anderson. 2001. History of the development of arsenic derivatives in cancer therapy. Oncologist 6(Suppl. 2):3-10.
38. World Health Organization. 1997. Hepatitis C: global prevalence. Wkly. Epidemiol. Rec. 72:341-344.
39. Yeh, C. T., H. Y. Lai, T. C. Chen, C. M. Chu, and Y. F. Liaw. 2001. Identification of a hepatic factor capable of supporting hepatitis C virus replication in a nonpermissive cell line. J. Virol. 75:11017-11024.
40. Zhu, J., Z. Chen, V. Lallemand-Breitenbach, and H. De The. 2002. Timeline: how acute promyelocytic leukaemia revived arsenic. Nat. Rev. Cancer 2:705-714.
41. Zhu, Q., J. W. Zhang, H. Q. Zhu, Y. L. Shen, M. Flexor, P. M. Jia, Y. Yu, X. Cai, S. Waxman, M. Lanotte, S. J. Chen, Z. Chen, and J. H. Tong. 2002. Synergic effects of arsenic trioxide and cAMP during acute promyelocytic leukemia cell maturation subtends a novel signaling cross-talk. Blood 99:1014-1022.